ArticleNature communications2026
Versatile and sensitive detection of mono- and poly(ADP-ribosyl)ation reveals XRCC1-dependent remodelling of PARP1 signalling.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- ADP-ribosylation: An emerging regulator of the epigenome.Molecular oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
ADP-ribosylation has long been recognised as a key regulator of essential signalling pathways, including the DNA damage response. However, only recent and ongoing technological advances are beginning to make it possible to investigate its distinct forms with molecular precision. Here, we design a 'mono-ADP-ribosylation blocking' strategy to develop sensitive, modular antibodies with high specificity for poly(ADP-ribosyl)ation. During peptide antigen generation, we identify a distinctive mass spectrometric signature that enables accurate mapping of poly(ADP-ribosyl)ation sites and helps prevent site mislocalization. Moreover, we affinity-mature mono-ADP-ribosylation and histone H3 site-specific antibodies. These tools reveal that, upon DNA damage, XRCC1 deficiency dramatically elevates the mono-ADP-ribosylation wave of PARP1 signalling, in addition to increasing poly(ADP-ribosyl)ation. This PARP1 hyperactivation leads to an increase in an unconventional form of ubiquitylation, recently shown to directly target mono-ADP-ribose in the DNA damage response and other signalling pathways. Consequently, XRCC1 loss enhances the recruitment of RNF114, the reader of this composite modification, to DNA lesions. These findings establish mono-ADP-ribosylation - and its ester-linked ubiquitylation - as key modifications induced by XRCC1 deficiency during DNA damage, revealed using tools we developed for precise and sensitive ADP-ribosylation detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.